GLOW: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. GLOW combines three research compounds — BPC-157, TB-500, and GHK-Cu — none of which are approved by Health Canada or the FDA for the research applications described in this guide.

Last updated: July 2026

---

GLOW takes the Wolverine Blend’s two-compound repair pairing and adds a third component with a genuinely different job: GHK-Cu, which doesn’t drive repair the way BPC-157 and TB-500 do, but supplies and protects the structural material — collagen, elastin — that repair is actually built from. This guide covers what changes, practically and evidentially, once GHK-Cu enters the mix.

Quick Facts

Contains	BPC-157, TB-500, and GHK-Cu
Common ratio	50mg GHK-Cu : 10mg TB-500 : 10mg BPC-157 (70mg total) — other ratios exist in the market
Primary research use	Tissue repair and recovery, with added structural/collagen support
Administration	Subcutaneous
Typical effective range (community-reported)	2.5mg combined dose, once daily
Evidence tier	Same as the three individual compounds — no blend-specific human trials exist
Regulatory status	All three components discussed in this guide series’ regulatory guides; BPC-157 and TB-500 are WADA-prohibited, GHK-Cu is not

Why This Third Compound, Specifically

BPC-157 and TB-500 address repair from two active angles — one triggering local repair processes, one mobilizing systemic repair resources. GHK-Cu adds something neither of those two compounds does directly: support for the structural and antioxidant environment repair actually depends on. It promotes collagen and elastin synthesis and activates the body’s antioxidant enzyme systems — less about triggering repair, more about making sure the materials and conditions for quality repair are actually available.

The practical framing that shows up consistently in community and vendor discussion: BPC-157 and TB-500 activate and mobilize the repair process, while GHK-Cu supports the structural rebuilding that process is working toward. This is why GHK-Cu is included at a notably higher proportion than the other two in most GLOW formulations — a 50mg:10mg:10mg ratio isn’t an accident, it reflects GHK-Cu’s role requiring a larger relative dose to be meaningfully represented alongside the much smaller effective doses of BPC-157 and TB-500. For each compound’s full individual profile, see our dedicated BPC-157, TB-500, and GHK-Cu guides.

The Evidence, As a Combination

As with the Wolverine Blend, there is no human trial evidence for GLOW as a specific three-compound combination. What exists is the individual evidence base for each component — covered in full in their respective guides — plus the same small amount of combined preclinical work on BPC-157 and TB-500 together described in our Wolverine Blend guide. GHK-Cu’s addition doesn’t have blend-specific combined research behind it either; its inclusion rests on mechanistic complementarity (structural support alongside active repair) rather than a trial demonstrating the three together outperform any subset of them.

Worth restating a point from GHK-Cu’s own guide, since it applies directly here: GHK-Cu’s strongest human evidence is for topical use, not the injectable, systemic application it’s actually included for in this blend. That evidence gap doesn’t disappear by combining GHK-Cu with two other compounds — it’s simply one more layer in a blend where none of the three components has strong direct human trial support for injectable use.

Who Shouldn’t Use This

This blend combines the individual cautions of all three components — there’s no blend-specific safety profile beyond the sum of its parts, and in GHK-Cu’s case, one genuinely distinct addition.

• Personal history of cancer or active malignancy. BPC-157 and TB-500 both carry the same theoretical pro-angiogenic caution individually; combining them with GHK-Cu doesn’t reduce that concern.
• Wilson’s disease. This is specific to the GHK-Cu component and doesn’t apply to BPC-157 or TB-500 individually — but it applies to this blend as a whole given GHK-Cu’s inclusion, given the compound’s copper content.
• Competitive athletes subject to drug testing. BPC-157 and TB-500 are both independently confirmed on the WADA Prohibited List at all times. GHK-Cu is not currently flagged. Using this blend still carries the same anti-doping exposure as using BPC-157 or TB-500 alone — GHK-Cu’s inclusion doesn’t change that.
• Pregnancy or breastfeeding. No human safety data exists for any of the three components in this context.

See our individual BPC-157, TB-500, and GHK-Cu guides for the complete picture on each compound’s specific safety considerations.

Common Myths, Addressed

“GLOW has been specifically tested and shown to work as a combination.” Not accurately — no blend-specific human trials exist for any subset of these three compounds together, let alone all three.

“GHK-Cu’s strong human evidence means this blend is better-evidenced than Wolverine.” Not quite — GHK-Cu’s strongest evidence is topical, not injectable. Adding it doesn’t meaningfully strengthen the blend’s overall human evidence picture for the systemic, injectable use this product is actually sold for.

“You can combine GHK-Cu with BPC-157 and TB-500 from separate vials into one syringe, the same way you can with Wolverine.” Worth a brief caution rather than an assumption either way — GHK-Cu’s stability and pH profile differ from the other two, so if you’re drawing from separate vials, it’s simpler and safer to inject each compound separately rather than combining them in one syringe. In practice, most researchers running multiple compounds inject them separately anyway, so this rarely changes much about how a protocol is actually run.

What Researchers Are Actually Experiencing

Community-reported tolerability for GLOW largely mirrors the individual components — injection site reactions as the most commonly noted effect, with GHK-Cu’s addition bringing its own well-tolerated profile rather than introducing new concerns.

One specific, useful visual quality check applies to this blend that doesn’t apply to Wolverine: a genuine GLOW solution should show a visible blue or blue-green tint from the GHK-Cu component. A solution that comes out clear and colorless where you’d expect that tint is worth questioning — the same quality signal described in our GHK-Cu guide applies directly here.

This section reflects patterns commonly discussed across community research spaces. It’s observational rather than clinical trial data, and individual experience varies.

The Practical Basics

Research Ranges

Protocol	Combined Dose	Frequency
Conservative	2mg	Once daily
Standard	2.5mg	Once daily
Higher	5mg	Once daily

These figures describe the total combined dose across all three compounds at whatever ratio the specific product is blended to — not an equal split between the three. Confirm your specific product’s ratio before calculating your draw, since ratios vary meaningfully between vendors (some formulations skew more heavily toward GHK-Cu than others).

Worked Dose Math

At a 70mg total blend (50mg GHK-Cu, 10mg TB-500, 10mg BPC-157) reconstituted with 2mL BAC water — fitting comfortably within a standard 3mL vial — the combined concentration is 35mg/mL:

• 2mg combined dose → 0.057mL → ~6 units
• 2.5mg combined dose → 0.07mL → ~7 units
• 5mg combined dose → 0.14mL → ~14 units

At this ratio, a 2.5mg combined dose delivers roughly 1.8mg GHK-Cu, 0.36mg TB-500, and 0.36mg BPC-157 — proportional to the 5:1:1 ratio the vial was blended to.

The underlying rule is the same as any single-compound calculation: volume (mL) = dose (mg) ÷ concentration (mg/mL), then ×100 for units on a U-100 syringe — just remember the dose figure here refers to the combined total across all three compounds, delivered proportionally at whatever ratio your specific product uses.

Vial Planning

A 70mg vial at 35mg/mL gives you 70mg combined total. At a steady 2.5mg combined dose per day, that’s roughly 28 days per vial.

Reconstitution and Storage — The Short Version

GLOW reconstitutes with standard BAC water, refrigerates at 2–8°C, and should be used within 28 days — the same standard approach used across nearly every compound in this series. One deviation worth carrying over from GHK-Cu’s individual guide: protect this blend from light somewhat more deliberately than a BPC-157/TB-500-only product, given the copper component’s mild light sensitivity. For the complete general process, see our dedicated reconstitution and storage guide.

Sourcing

A complete Certificate of Analysis for a three-compound blend should independently confirm the identity and purity of all three components — a single overall purity figure tells you meaningfully less here than it would for a single-compound product. See our full guide on reading a Certificate of Analysis and vetting a vendor for the general framework this builds on.

Administration

Subcutaneous injection, once daily. No fasting requirement.

Best Practices

• Verify all three components independently on the COA — this matters even more here than for a two-compound blend.
• Check for the expected blue-green tint before each use as a quick, free quality signal.
• Track your protocol from day one — combined dose, injection date, and observed effects, at minimum.

Blend vs. Buying Separately

The core tradeoff here is the same one described in our Wolverine guide: a fixed ratio you can’t independently adjust, and a COA that requires more careful reading to confirm all three components rather than one. If your research plans call for adjusting GHK-Cu’s proportion independently of BPC-157 and TB-500, that flexibility requires managing separate vials — which is straightforward, since most researchers running multiple compounds administer them as separate injections rather than combining everything into one syringe regardless.

Common Mistakes to Avoid

• Assuming the ratio is standardized across vendors — GLOW formulations vary (50:10:10, 35:10:5, and others are all sold), so confirm your specific product’s ratio before calculating doses.
• Treating “combined dose” as an equal three-way split — the actual delivered amount of each compound depends on the blend’s specific ratio, not an even division.
• Not recording the reconstitution volume, turning every future dose calculation into a guess.

What Happens If You Stop

As with each individual component, there’s no dedicated discontinuation research for this blend. Consistent with how BPC-157 and TB-500 are typically used — tied to a specific recovery objective — and how GHK-Cu is more often framed as an ongoing addition, most community use of GLOW follows the recovery-focused compounds’ pattern: use tied to a defined protocol window, tapering or discontinuing once the objective is met.

What to Expect, Week by Week

This follows a similar pattern to the Wolverine Blend for the repair-focused components, with GHK-Cu’s structural and skin-related effects — where relevant to your research objective — generally described as more gradual, consistent with what’s discussed in our GHK-Cu guide’s own timeline section.

Combining With Other Compounds

GLOW is itself a combination product, so “combining” here generally means deciding whether to add KPV on top of it — which is exactly what KLOW does, covered in its own guide elsewhere in this series. Outside of that specific extension, GLOW is not commonly discussed as a component of broader multi-category stacks the way individual compounds like BPC-157 or CJC-1295 are.

Common Questions

Why does GHK-Cu make up such a large proportion of the blend compared to BPC-157 and TB-500? GHK-Cu’s effective doses are simply larger in absolute terms than BPC-157’s or TB-500’s, so a meaningful relative contribution requires a much larger milligram amount — this is consistent with GHK-Cu’s individual guide, where it’s noted as coming in larger vial sizes than most other compounds in this series.

Can I combine GLOW with additional BPC-157 or TB-500 if I want more of just those two? This is a reasonable approach, but it means managing an additional separate vial rather than relying on the blend alone.

Is GLOW just Wolverine with GHK-Cu added? Functionally, yes — it’s the same underlying repair-and-mobilization rationale as Wolverine, with a structural-support component added. The formulation is specifically designed to keep all three stable together, which is part of why it’s not simply “Wolverine plus a GHK-Cu vial added at home.”

Is GLOW legal to source in Canada? Each component is subject to the considerations described in our Canadian regulatory guide. Combining them into one product doesn’t change the underlying status of any individual compound.

Before You Start

A quick checklist to run through before your first dose:

• [ ] Reviewed the individual contraindications for BPC-157, TB-500, and GHK-Cu, including the Wilson’s disease consideration specific to GHK-Cu
• [ ] Confirmed you’re not subject to competitive drug testing, or accepted that risk knowingly given the BPC-157/TB-500 components
• [ ] Confirmed your COA verifies all three compounds independently
• [ ] Confirmed your specific product’s ratio, since formulations vary between vendors
• [ ] Checked for the expected blue-green tint as a quick quality signal
• [ ] Have a tracking method ready for combined dose, injection date, and observed effects

Want this as a printable checklist alongside our compound reference plate? Download both from the resources section.

Common Protocol at a Glance

Protocol	Combined Dose	Frequency
Conservative	2mg	Once daily
Standard	2.5mg	Once daily
Higher	5mg	Once daily

Where to Go From Here

• BPC-157: The Complete Guide
• TB-500: The Complete Guide
• GHK-Cu: The Complete Guide
• The Wolverine Blend — the two-compound version this builds on
• KLOW — the four-compound extension of this blend
• The Regenerative Compound Group — all four individual compounds compared in full
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.